The Death of Cancer

In recent years, through many articles and activities, we have tried to explain that cancer has become largely preventable and treatable. While spreading this awareness, we recognize cancer causes deaths, but compared with 50 years ago treatment has advanced by an era, and cancer’s fate has begun to change. Although a precise timeframe is difficult, experts believe cancers will be completely treatable within the next 50 years. Dr. Vincent T. DeVita, a renowned physician who personally witnessed the last 50 years of cancer treatment and himself fought the disease, wrote “The Death of Cancer.” We wanted to share a translation of a valuable interview about this book.
Maurie Markman, Dr: Hello. Our interview is with Dr. Vincent T. DeVita, one of oncology’s most influential researchers and physicians. Recipient of many awards, he is known for developing a 4-drug treatment for Hodgkin lymphoma and helping launch modern chemotherapy in the mid-1960s. Colleagues called this one of modern oncology’s greatest advances. He recently wrote “The Death of Cancer,” recounting his experiences in research and treatment.
As a leading oncologist, Dr. DeVita reveals in his book why cancer is a beatable diseaseand how we can reach that point. My first question, which many want answered, is: Why did you write this book?
Vincent T. Devita Jr, Dr: As you know, the American public paid over 100 billion dollars in taxes fighting cancer. I felt I was in the right place at the right time. I was at the Cancer Institute then, and my job was to get philanthropist Mary Lasker interested in cancer. I later ran the entire program and two outside cancer centers. Then I had the opportunity to become President of the American Cancer Society.
As if I had not gained enough experience, I developed cancer myself. I said, “I must do this. Someone in this position should really recount their experiences, so people with cancer would know what they got for their money from someone who actually experienced it and recovered.” So I did, with my daughter Elizabeth, a wonderful writer. I wanted her to keep me honest and help translate what I did. This book was written for the public, not doctors and nurses. Some thought it was only for doctors and nurses, but that is not true. That is why I wrote it.
Maurie Markman, Dr: I really want to thank you. Writing this for the public is admirable. What is the main message you give and want to give readers?
Vincent T. Devita Jr, Dr: The main message is what you already mentioned: the war against cancer is not only winnable; it is actually being won. People do not appreciate the important changes in cancer since 1971.
Since 1971, of 100 billion dollars, we invested 65% in supporting research, a tremendous amount for research. Cancer incidence and mortality have been declining since 1990-1991. Treating cancer has never been easy, but disease rates are much lower than before.
One major advance was in breast cancer early diagnosis and treatment. Breast cancer mortality fell 25%. Overall cancer mortality in developed countries fell 25%. It is probably greater now because these data are 5 years old. When rates for 2016 are calculated with new approaches such as targeted therapies and immunotherapies, it is probably around 35%. This is very steady progress.
So the message is: We are not only beating cancer; cancer is also beatable.
Maurie Markman, Dr: Right.
Vincent T. Devita Jr, Dr: This is only reaching clinics; the best has not yet arrived. We know things will improve. We need optimistic messages for people. One reason for confusion is that, when treating cancer, we ask people to go home and live normally, and they do. Most do not go around saying “I have cancer and I…” Some do, some become activists, but most do not. Those you see are usually those suffering from the disease and are more conspicuous. People do not appreciate how many recover from their type of cancer.
Maurie Markman, Dr: That is an important, positive message. Although you clearly said this book is for the public, do you also have or did you have a message for physicians, oncologists and/or health professionals?
Vincent T. Devita Jr, Dr: As I say in the book, some doctors are unenthusiastic about cancer treatment. Some patients put themselves in the hands of physicians who do not believe. If you are newly diagnosed and your doctor says, “You have cancer; there is nothing I can do,” find another doctor, because today something can be done for everyone with cancer.
Maurie Markman, Dr: It is a wonderful book, your daughter is an excellent writer, and you have written a wonderful story together. Again, it is written for the public.
Vincent T. Devita Jr, Dr: That is why we wrote it this way; my daughter is talented at shaping and coloring a story. I think I mentioned writing 320,000 words, three times the current length. I gave her the draft and she returned 110,000 words. Now the book is readable. She said, “There is no point writing a book if nobody will read it.” It is much more readable this way. Without her, it would have been entirely different.
Maurie Markman, Dr: Some discussions in the book, particularly the “concept of cure,” deserve your comment. You clearly state cancer is beatable and support talking about cure. Would you comment?
Vincent T. Devita Jr, Dr: I have noticed colleagues hesitate to use “cure.” I am somewhat unconventional at Yale. “We do not know whether you will recover” is very standard. It is partly fear: if we encourage the patient about cure and cancer recurs, you bear responsibility.
I think patients prefer complete freedom from cancer. They do not want to hear “You will not recover” or “We are not sure.” They want to go home and feel comfortable. In almost every cancer, there is a period after treatment beyond which, if it has not recurred, you know recurrence is unlikely.
For Hodgkin disease, for example, this is about 4 years. Patients enter remission (complete disappearance of cancer signs and symptoms), remain there, and receive no treatment for 4 years. I feel they should be told they will be cured and given optimism.
Interesting things are happening. The best example I know is chronic myelocytic leukemia, a very deadly disease. We can achieve remission quickly, but it remains deadly. Patients now take chemotherapy pills and live normally. If they develop resistance, industry has developed 4 other drugs, and we will probably keep doing so. Even without cure, disease can always remain under treatment, allowing normal lives.
We have different patient categories: some living normally with cancer and others without cancer. We will see more of this. With some immunotherapies, cancer does not progress, but careful examination shows disease signs remain. This is a new category, and the difference must be explained. But when we can confidently say they recovered, I would say, “You know, you are very probably cured.”
Maurie Markman, Dr: Vincent, you are open, honest and emotional describing your cancer and your son’s illness. How did this affect you? How did you feel then and now about the future?
Vincent T. Devita Jr, Dr: My son had anaplastic anemia. He was put in a laminar airflow room against infection, staying about 8 years apart from short trips. We worked with NASA and took him out in a spacesuit. He never left that room. I thought I empathized with families whose children had leukemia or died from it, but experiencing it yourself is entirely different. It made me a better physician and changed me in many ways.
I developed prostate cancer and did what many doctors do: ignored it, “do as I say, not as I do.” Eventually diagnosed, mine was difficult; the prostate was very large. I could not do for myself what I normally do for patients—referrals and finding the best care. I asked colleague Dr. Steve Rosenberg to do this. He did excellently, referring me to Dr. Peter Scardino, one of the country’s best surgeons. This showed me the inside of healthcare; I knew it was hard, but personal experience is different. It changed me considerably.
Maurie Markman, Dr: You discussed controversies throughout your career, beginning with resistance to combination chemotherapy. Why reluctance toward approaches now standard? I see little enthusiasm for new ideas and much resistance. Your thoughts?
Vincent T. Devita Jr, Dr: Let us divide it in two. First, in the 1960s, curing cancer with drugs was considered madness and doctors doing it mad. Methods were inadequate. Descriptions of those persistently trying were extraordinary.
I was young, from a university where nobody would tolerate this. It was called madness. Combining drugs was considered medically wrong. This first arose with antibiotic combinations, which were relatively useful. Combining toxic cancer drugs, when people thought nothing could be done and it would only make patients sicker, seemed outlandish.
We worked at the National Cancer Institute, a protected setting where we could do this, criticized but not stopped. Elsewhere you were constrained; it was impossible. I took leave to finish residency at Yale and tried some there. I was told unequivocally it was madness and returned to the National Cancer Institute.
I see the same today. People still resist innovation. Evidence shows different drug combinations are needed to cure cancer. With few exceptions, combination treatment is necessary. Today, combined melanoma immunotherapy gives better results than a single immunological agent.
I do not know why we must prove it anew each time, but we do because the FDA requires it. I think the FDA remains in the last century and needs to enter this one. We discuss this extensively. We are overly regulatory. Doctors fear punishment, loss of research permission or authority if they do something unconventional.
Maurie Markman, Dr: You expressed concerns about the FDA in your book. How can we change this? I sense frustration. Advances are incredible, potential advances greater. Yet we are in this slow environment. The FDA and rules go back 60 years. What can we do?
Vincent T. Devita Jr, Dr: I tried by writing a book, hoping to attract people who can fix it—Congress. Physicians do not realize where they are: trapped where the FDA practices medicine and manages research. Chemotherapy manuals say “approved after this drug, before that drug.”
Someone 4.800 km from the patient tells you exactly when to use a drug. Much innovation loses momentum during marketing. The FDA paralyzes the postmarketing period. I propose a simple solution in the book: the FDA and National Cancer Institute (NCI) should transfer all phase I and II trials entirely to cancer centers. FDA and NCI can retain inspection and oversight rights they already have, but should delegate all responsibility. You could start phase I trials at your center without going back, making changes through your internal review committee rather than returning to the FDA or NCI. The same applies to phase II studies producing many good results.
I also think the FDA must change how it approves drugs. Approval should be based on safety, assessed for the patient who will use it. Safety affects the patient’s future life. Safety and what a drug can do to hit its biological target matter.
When you develop a drug or receptor you know is important, if the drug hits the receptor they should approve it. You place it in physicians’ toolbox, and doctors can mix and match drugs as desired. Recently I attended a meeting of the “Society of Babbling Idiots,” the best meeting of my career. It was a war room discussing all data. Laboratory data were matched and we adjusted the protocol. Obtaining such adjustments through review systems can now take 800 days.
Delegate this to cancer centers. Each creates its own “Society of Babbling Idiots,” knows biological pathways and all mutations, and mixes and matches treatments.
Most interestingly, this makes things easier and less expensive. You do not need to launch a rocket to the moon; the FDA and National Cancer Institute need only relinquish some authority and power. Unfortunately, conversely, institutions in Washington D.C. voluntarily relinquish their power and authority.
Although I criticize cancer centers in the book for causing difficulties, many are now capable of doing this easily. They have far more experts than the FDA has ever had. These research studies and programs providing drugs before licensing should be taken from the FDA and returned to their place in the 1970s.
Maurie Markman, MD: You clearly express frustration and experiences in cancer centers. Is their culture changing, particularly more academic matrix institutions not entirely focused on cancer? Is this changing?
I think the question is: “Do we need to think more broadly about cancer centers rather than their cost—their organization and operation, who is responsible, how and why to fund them?”
Vincent T. Devita Jr, MD: Yes and yes. A long answer could take an hour. Yes. I am at Yale and criticize it considerably. I have perspective and can explain when something goes wrong. We have come far, and I emphasize we are much better at implementing research results.
When I went to Yale, they were concerned about research. Implementation was neglected and difficult. Roy Herbst now leads medical oncology and does an excellent job translating results. Yes, it is changing.
But not everywhere. I recently experienced a cancer center with no team spirit. In all our centers, people work as teams; with lung cancer, you see the team. This center had no team; patients simply went from one physician to another. We have come far. I think trials can be delegated to centers.
Maurie Markman, MD: Returning to research, I want you to look into your crystal ball—unfair, but I will ask. We discussed immunotherapy. Years ago we worked in immunology thinking we could cure cancer. Remember BCG and neuraminidase (a glycoside hydrolase enzyme) tumor cell research? Looking back, we say “I cannot believe it.” Where we are now is incredible. We learned much. There are precision drugs, genomics and proteomics. Where will this go? Immunotherapy, targeted therapy or combination treatment? Based on experience and observation, what do you think?
Vincent T. Devita Jr, MD: I called it “The Death of Cancer.” I examined the 8 hallmarks described by Dr. Weinberg and Hanahan. They say, “When successful, we attack 2 or 3 hallmarks.” In future we will attack all. Immunotherapy is only one. Lack of immune surveillance is one. Discovery of checkpoint inhibitors in 1996 changed our thinking. We struggled for years to understand why we could not suppress the immune system to eradicate cancer.
When Dr. Steve Rosenberg administered IL-2 with lymphocyte infusions, 10% or 15% of patients had excellent responses, while the rest had none. We could not understand. Jim Allison, PhD, solved this by demonstrating checkpoints.
Checkpoint inhibitors are now available and have changed immunotherapy. I do not believe immunotherapy alone is cancer’s answer. If free to combine, it will be paired with chemotherapy and other methods. As I wrote about nondiscriminating treatments, “good luck in the current regulatory environment.”
The FDA forces companies to test drugs individually. What is needed is testing combinations together.
Maurie Markman, MD: Can we fix this? Yes.
Vincent T. Devita Jr, MD: Delegating phase I and phase II studies to cancer centers lets you do what is needed in any way. We must ensure patient safety and effective management. It can be fixed quickly and more cheaply. We have an idea that could work, cost less and improve the reasons preventing cancer treatments.
Maurie Markman, MD: Your comments on prevention: it is difficult. From your perspective, what is its future?
Vincent T. Devita Jr, MD: Yes. Nobody wants cancer. Proving negative studies is difficult, and prevention studies are expensive. At the National Cancer Institute, when I first considered high-fat diets and breast cancer, people urged prevention spending. We said we would develop a trial comparing low-fat and standard diets to see whether breast cancer rates could fall.
We worked on it; I presented data to the board: “Do you want to do it? We need approval. This will cost $150 million.” They nearly died: 150 million and success chances between slim and none. These trials are expensive and results less robust than desired. One thing is certain: stopping smoking greatly reduces cancer mortality risk.
Many recent articles concern bacon and colon cancer risk. People email, “What do you do?” It is true that daily bacon may slightly increase colon cancer risk. But telling a smoker to stop bacon and eat less meat without telling them to quit smoking—what happens? On that balance, bacon consumption falls and smoking soars. We know preventing smoking works. Lung cancer mortality drops greatly with cessation.
We can continue this decline. Complete smoking cessation could reduce cancer mortality by another 30%. Otherwise, it is very difficult. Chemoprevention drugs appear to accelerate risk reduction. Chemoprevention in people quitting smoking is underresearched. After quitting, lung cancer risk takes 15 years to decline to that of never-smokers; perhaps 10 years for head and neck cancer. It still takes time.
Could chemoprevention accelerate reduction from 15 years to 5 years? We lack research and I think we cannot do this. Two things may matter: cancer can be delayed, and this strongly motivates quitting. People ask, “I smoked so long; what difference will it make?” The answer: “Much changes immediately. If you quit and use chemoprevention, perhaps all risk could disappear within 5 years.”
Maurie Markman, MD: How did it feel to be named one of cancer treatment’s giants a few years ago?
Vincent T. Devita Jr, MD: It is a great honor. Recognition among colleagues is wonderful, and the company is strong. All the people I admired for years were in that group and continue joining. I think people eagerly wait to be considered a cancer treatment giant one day.
Maurie Markman, MD: Vincent, as a longtime teacher, medical leader and researcher, what would you call the major advances and discoveries?
Vincent T. Devita Jr, MD: There is much to say, but in cancer treatment, I think 3 paradigms changed things profoundly. First, curing advanced cancer with combination chemotherapy. This opened adjuvant treatment for colorectal and breast cancers.
Second, Brian Druker put the drug targeting the Bcr-Abl mutation in myelocytic leukemia on the targeted therapy map. This brought targeted treatment. We now sequence genomes, identify targets and use this approach in lung cancer, melanoma and many cancers.
Third, discovering immunotherapy checkpoints. These are the 3 paradigms profoundly changing cancer treatment.
Maurie Markman, MD: A final question. What do you do these days? I know you wrote a book and speak at events. How do you spend your time?
Vincent T. Devita Jr, MD: We published “Principles and Practice of Oncology” and are starting the 11th edition. I do not know why, but it is enjoyable and keeps me current. We prepared it as 3 editors; exhausting but important, and it consumed my time. The book took much time. I consult patients but no longer follow them, handing cases to younger doctors who can. I also teach. One benefit of aging is more time to sit, look at the field and assess.
Maurie Markman, MD: Vince, I cannot thank you enough. As my teacher and that of future medical, surgical and radiation oncologists, and for what you do for current and future patients, you truly are a giant. Knowing and working under you is an honor. Thank you.
Vincent T. Devita Jr, MD: Very kind, Maurie. Good to see you.
Maurie Markman, MD: Thank you; my pleasure.
Sources
https://global.onclive.com/onclive-tv/dr-devita-discusses-the-death-of-cancer/
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.